Despite the slightly warmer weather and longer periods of sunshine, we are still in the depths of cold and flu season, a ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Flu and RSV are packing a post-holiday one-two punch, sending people into Erie's emergency departments and medical offices ...

“Watched my baby with a tube down his throat for eight days and wasn’t sure if I was ever going to hold him again,” Elliot’s ...

7. New RSV prevention options for infants and pregnant mothers A new RSV prevention option for infants was introduced in 2023: the monoclonal antibody treatment Beyfortus (nirsevimab). This shot is ...

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

Dr. Simon Drysdale, a co-leader of the HARMONIE trial, emphasised the treatment’s impact: “The thousands of winter hospital admissions caused by RSV are highly distressing for families and ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...